Sutro Biopharma (NASDAQ:STRO) Raised to "Sell" at Wall Street Zen

Key Points

• Wall Street Zen upgraded Sutro Biopharma from “strong sell” to “sell,” while the broader analyst consensus remains “Buy” with a $49.50 price target.
• Analyst opinions are mixed: Stifel Nicolaus, HC Wainwright, Citigroup, Citizens JMP, and Wedbush maintain bullish ratings, with price targets ranging from $34 to $60.
• Sutro shares opened at $9.10, near their $7.15 one-year low, after the company reported a quarterly loss of $2.33 per share and revenue of $9.84 million, both below analyst expectations.

Sutro Biopharma (NASDAQ:STRO - Get Free Report) was upgraded by research analysts at Wall Street Zen from a "strong sell" rating to a "sell" rating in a research report issued to clients and investors on Saturday, Wall Street Zen reports.

STRO has been the topic of several other research reports. Stifel Nicolaus set a $48.00 price target on shares of Sutro Biopharma and gave the company a "buy" rating in a report on Friday, August 7th. Citigroup reissued a "market outperform" rating on shares of Sutro Biopharma in a research note on Thursday, August 13th. HC Wainwright restated a "buy" rating on shares of Sutro Biopharma in a research report on Friday, October 16th. Citizens Jmp reduced their target price on Sutro Biopharma from $41.00 to $34.00 and set a "market outperform" rating on the stock in a research note on Thursday, August 13th. Finally, Wedbush reiterated an "outperform" rating and set a $60.00 target price on shares of Sutro Biopharma in a report on Thursday, October 15th. Two analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Sutro Biopharma currently has a consensus rating of "Buy" and a consensus price target of $49.50.

Sutro Biopharma Stock Performance

Shares of STRO stock opened at $9.10 on Friday. The stock has a fifty day moving average price of $15.39 and a 200 day moving average price of $22.77. The stock has a market cap of $150.88 million, a PE ratio of -0.76 and a beta of 1.49. Sutro Biopharma has a 1 year low of $7.15 and a 1 year high of $43.85.

Sutro Biopharma (NASDAQ:STRO - Get Free Report) last announced its quarterly earnings results on Wednesday, August 12th. The company reported ($2.33) earnings per share for the quarter, missing analysts' consensus estimates of ($2.19) by ($0.14). The firm had revenue of $9.84 million during the quarter, compared to analyst estimates of $11.96 million. As a group, equities research analysts predict that Sutro Biopharma will post -8.41 earnings per share for the current year.

Institutional Trading of Sutro Biopharma

A number of hedge funds have recently bought and sold shares of the company. Wellington Management Group LLP bought a new stake in shares of Sutro Biopharma in the second quarter worth approximately $359,000. Sigma Planning Corp bought a new position in Sutro Biopharma during the first quarter valued at approximately $312,000. Bank of America Corp DE lifted its position in Sutro Biopharma by 348.1% during the first quarter. Bank of America Corp DE now owns 18,873 shares of the company's stock valued at $470,000 after purchasing an additional 14,661 shares during the period. Stempoint Capital LP purchased a new stake in Sutro Biopharma in the first quarter worth approximately $580,000. Finally, Bank of New York Mellon Corp purchased a new stake in Sutro Biopharma in the second quarter worth approximately $1,373,000. Institutional investors and hedge funds own 96.99% of the company's stock.

Sutro Biopharma Company Profile

Sutro Biopharma, Inc is a clinical-stage biotechnology company focused on developing medicines for cancer and other serious diseases. The company uses its proprietary XpressCF cell-free protein synthesis platform to design and manufacture targeted biologic therapies, including antibody-drug conjugates (ADCs) and cancer immunotherapies.

Sutro's research programs have included luveltamab tazevibulin, also known as STRO-002, a folate receptor alpha-targeted ADC being investigated for ovarian and endometrial cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.